HTB 30 September 2019 online
This edition of HTB includes a few final reports from IAS 2019.
We follow with news of first UK access (in Scotland) to the new two-drug combination of dolutegravir/lamivudine and that the US FDA approve doravirine-based ART as a switch option.
A review paper from CID continues the evidence looking at whether integrase inhibitors are linked to weight gain – also reported from IAS 2019.
WHO have issued new guidelines for on-demand PrEP and joint UK guidelines cover the legal evidence to challenge HIV discrimination that is still sometimes reported at tattoo and beauty salons.
Finally, two articles in other news, show community concerns about HIV services and the negative impact from lower uptake of the measles vaccination in the UK.